ISSN 1671-5411 CN 11-5329/R
Volume 17 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Zhuang TIAN, Chao REN, Li HUO, Xiao LI, Yi-Ning WANG, Lun HUANG, Ran TIAN, Shu-Yang ZHANG. Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly. J Geriatr Cardiol 2020; 17(12): 793-796. doi: 10.11909/j.issn.1671-5411.2020.12.010
Citation: Zhuang TIAN, Chao REN, Li HUO, Xiao LI, Yi-Ning WANG, Lun HUANG, Ran TIAN, Shu-Yang ZHANG. Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly. J Geriatr Cardiol 2020; 17(12): 793-796. doi: 10.11909/j.issn.1671-5411.2020.12.010

Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly

doi: 10.11909/j.issn.1671-5411.2020.12.010
More Information
  • loading
  • [1]
    Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009; 120: 1203-1212. doi: 10.1161/CIRCULATIONAHA.108.843334
    [2]
    Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019; 12: e006075.
    [3]
    Mohammed SF, Mirzoyev SA, Edwards WD, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2014; 2: 113-122. doi: 10.1016/j.jchf.2013.11.004
    [4]
    González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-2594. doi: 10.1093/eurheartj/ehv338
    [5]
    Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail 2019; 6: 1128-1139. doi: 10.1002/ehf2.12518
    [6]
    Phelan D, Thavendiranathan P, Popovic Z, et al. Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr 2014; 27: 888-895. doi: 10.1016/j.echo.2014.04.015
    [7]
    Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-193. doi: 10.1161/01.CIR.0000152819.97857.9D
    [8]
    Singh V, Falk R, Di Carli MF, et al. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 2019; 26: 158-173. doi: 10.1007/s12350-018-01552-4
    [9]
    Bokhari S, Castaño A, Pozniakoff T, et al. 99mTC-Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013; 6: 195-201. doi: 10.1161/CIRCIMAGING.112.000132
    [10]
    Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404-2412. doi: 10.1161/CIRCULATIONAHA.116.021612
    [11]
    Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007-1016. doi: 10.1056/NEJMoa1805689
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)

    Article Metrics

    Article views (217) PDF downloads(14) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return